Jeonbuk National University researchers described an engineered Salmonella Typhimurium strain designed to kill aggressive breast cancer cells while stimulating an antitumor immune response in mouse models. The modified bacterium, JOL3136, was built by attenuating virulence through gene deletions and engineering tumor-localizing therapeutic payloads including apoptin and a CEA epitope. In 4T1 tumor experiments, the platform reduced tumor volume and mass compared with vector controls, alongside increases in IFN-γ and CD49b-positive lymphocytes within the tumor microenvironment. The work adds to the field’s continued exploration of live biotherapeutics as immune-engaging cancer modalities. Next steps for the translational path include defining safety margins, dose schedules, and biomarkers that show bacterial localization and immune engagement in a manner that can be carried into early clinical testing.
Get the Daily Brief